Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' Alcon Eyed By Lawsuit For Gender Inequality

This article was originally published in Scrip

Executive Summary

Novartis is facing another lawsuit regarding gender discrimination – this time from two former employees of the company's Alcon eye-care division. The two women allege in a complaint filed with the US District Court of the Southern District of New York that Alcon "discriminated against them on the basis of their gender" and are seeking $110m in reparations.

You may also be interested in...



Venter's Synthetic Genomics Sued For Gender Discrimination

Synthetic Genomics, co-founded by genomic pioneer Craig Venter, has been sued by its former intellectual property chief for gender discrimination – a claim that CEO Oliver Fetzer believes to be "without merit."

Women Wanted: Merck Faces Class Action In $250m Discrimination Case

A handful of former female sales representatives suing Merck & Co. Inc. for gender discrimination, including an alleged bias against employees who took maternity leave, could become a very large group of women now that the lawsuit seeking $250m in damages has been granted conditional certification as a collective action under the Equal Pay Act (EPA).

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Related Companies

UsernamePublicRestriction

Register

SC028149

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel